Does Qina Cure AIDS?

Cure as defined by the medical dictionary:- Restoration of health; recovery from disease. A method or course of medical treatment used to restore health. An agent, such as a drug or remedy that restores health. To effect a cure or recovery. To heal, to make well, to restore to good health.

AIDS is not a disease, but a classification. No one has ever died from AIDS but rather an AIDS related illness. To be classified as having AIDS, a person must be tested as being HIV positive as well as having a CD4 count of less than 200.
If therefore by using Qina, your CD4 count rises above the 200 level, then you have either been cured from AIDS or you have been declassified as an AIDS patient, the terminology is subjective.

Some of the statements made on this page have definitely ruffled some feathers mainly from the medical quarter that emphatically believe that the only treatment for AIDS is with Anti Retro Virals (ARV's). Because we have both clinical evidence and thousands of testimonials to the contrary we would be doing the public an injustice by not presenting Qina as a safe, effective and affordable treatment of HIV   AIDS.

There are only two ways of killing a virus, firstly a vaccine and secondly the immune system. There has been over thirty failed attempts to develop a vaccine and therefore the only logical approach is to utilize the immune system. It has been proven that Qina induces morphological alterations of macrophages within 24 hours. Apart from a decrease in tumor necrosis factor-alpha (TNFα) production, an increase in CD4   CD8 counts were observed as well as a reduction in viral loads.

What does this mean ?

The key indicators of a failing immune system is the CD4 count and the ratio of CD8 to CD4 levels associated with high viral loads. A patient can still die with a high CD4 count if associated with a high viral load. The key is to improve the CD4 count and reduce the viral load to avoid the potential of an opportunistic infection. In Aids/HIV cases, Qina promotes an increase in the number of active T and B lymphocytes, as well as the number of cytokines. Therefore, patients immediately respond to treatment, with a decrease in the incidence level of opportunistic diseases, such as pneumonia and other infections.
The viral burden is reduced to very low levels, becoming, in some cases, almost non-detectable. In addition to the specific efficacy on the immunologic stimulation against the infection, Qina provided quality of life to patients submitted to aggressive ARV therapies. For this reason, it may be used in association with other traditional treatments, such as Anti-Retro-Viral's, but reported accounts show better results prior to ARV intervention.

Results from the Qina studies - (randomized, placebo, double blind controlled)
  • 70% of Qina patients started with opportunistic infections. After 6 months this was reduced to 5%. The control group started with 45% infections which dropped to 22% after 1 month but then rose again to 35% after 6 months.
  • Only 20% of the Qina patients had a drop in viral loads less than 90%, while the control group had a 65% therapeutic failure.
  • CD 4 counts rose almost immediately within the first month and continued to rise after 6 months. The control group rose within the 1st month but leveled off between a range of 220 and 350.
  • Nausea and vomiting decreased within the first week and energy levels increased allowing patients who were bedridden the freedom to take part in active duties.
  • Improved appetite and weight gain in most patients was significant
  • In a quarter of the patients, Qina was used together with ARV's without significant incidence or side effects. Three quarters of patients used Qina alone with significant results especially on their physical well being as well as the improvement of CD4 and viral loads.
  • There was an overall improvement in the quality of life and all patients decided unilaterally to continue with the medication even after the trial had been completed.

  • A Scientific Study on HAART or Anti Retroviral Treatment

    The report published in The Lancet (2006; 368:451-458), shows that HAART does not reduce mortality rates for people with HIV. Analyzing information generated since the introduction of HAART, including data from over 20,000 patients, the study found that: “Virological response after starting HAART improved over calendar years, but such improvement has not translated into a decrease in mortality.”
    In other words, antiretroviral drugs are useful in boosting CD4 counts and decreasing viral loads, but these arbitrary surrogate markers are useless in determining clinical outcomes, and the drugs ultimately have had no effect on prolonging life.

    This study can mean one of three things:
    1. The toxic virocidal effects of the drugs are not worth taking.
    2. There may be other factors besides the virus.
    3. HIV does not cause AIDS.

    When to take Qina?

    As a preventative measure: Administration should commence prior to CD4 counts reaching the 200 level. This is probably the most important aspect to consider as there is currently no medical treatment in place to prevent ones CD4 count from dropping (prior to ARV intervention) other than to say "look after yourself and eat healthy." These words in themselves are good advice however they are not specific enough and usually a patient is left to his own devices. It is important to remember that once you are on ARV's it can be a very slippery path downwards.
    As an adjuvant measure: To be used in conjunction with ARV therapy to limit the toxic side effects.
    As an alternative: If you have abandoned the treatment or do not have access to ARV's.
    As a quality of life measure if you are "beyond therapeutic effect" and standard medical protocol has failed or been discontinued.